Was rhBMP-2 research tainted?

By Terry Stanton

The Spine Journal questions sponsored rhBMP-2 research

Orthopaedic surgeons took notice in late June when two members of the Senate Finance Committee sent a letter to Medtronic, Inc. (Minneapolis), maker of the recombinant human bone morphogenetic protein-2 (rhBMP-2) product Infuse. Sens. Max Baucus (D-Mont.) and Charles Grassley (R-Iowa) expressed concern about media reports that researchers conducting clinical trials on the product who had financial ties to Medtronic failed to report adverse events, including sterility in men and potentially harmful bone growth.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!